EpiCast Report: Psoriatic Arthritis - Epidemiology Forecast to 2025
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive in nature and can lead to severe joint damage and disability. The disease is considered to be rare in the general population, but PsA may affect up to 30% of persons with psoriasis (Ogdie and Gelfand, 2011; NPF, 2016).
In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of PsA will increase from 1,044,022 cases in 2015 to 1,107,253 cases in 2025, at an Annual Growth Rate (AGR) of 0.61%. The US will have the highest number of diagnosed prevalent cases of PsA among the 7MM throughout the forecast period, while Japan will have the least.
GlobalData epidemiologists provided an alternate forecast that models an increased diagnosis rate, as indicated by primary research involving high prescribing physician surveys. The results of the survey suggest that the diagnosis rate of PsA is likely to improve during the forecast period, from 2015-2025. Based on the alternative forecast of diagnosed prevalent cases, and using diagnosis rates obtained through primary market research, GlobalData epidemiologists forecast that in 2015 there were 1,044,022 diagnosed prevalent cases of PsA; this is expected to grow to 1,520,469 cases by 2025, at an AGR of 4.56%.
GlobalData’s forecast is strengthened by the use of peer-reviewed, country-specific publications, which provided the total number of diagnosed cases or diagnosed prevalent cases in each market. The use of studies that supplied diagnosed prevalence based on CASPAR criteria and medical records in countries where CASPAR is predominantly used provides a significant measure of the underlying burden of PsA in all of the 7MM. The use of a consistent methodology across the 7MM to forecast the diagnosed prevalent cases of PsA allows for a meaningful comparison of the forecast diagnosed prevalent cases of PsA in these markets. Additionally, GlobalData epidemiologists provided the diagnosed prevalent cases of PsA in each of the 7MM, segmented by type (symmetric, asymmetric, distal, spondylitis, and arthritis mutilans), which can be of importance for forecasting the prognosis and course of treatment.
Reasons to buy
- The Psoriatic Arthritis (PsA) EpiCast Report provides an overview of the risk factors and global trends of NSCLC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a base 10-year epidemiological forecast for the diagnosed prevalent cases. The diagnosed prevalent cases of PsA are further segmented by sex, age, type as defined by the Moll and Wright criteria (symmetric, asymmetric, distal, spondylitis, and arthritis mutilans), and by peripheral or axial joint involvement. Additionally, GlobalData epidemiologists include an alternate 10-year epidemiological forecast of the diagnosed incident cases of PsA based on primary market research, which includes an adjustment for an improving diagnosis rate over the forecast period.
- The PsA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The PsA EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global PsA market.
- Quantify patient populations in the global PsA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PsA therapeutics in each of the markets covered.
- Compare patient population potentials in various type and understand how might changes in diagnosis rate impact patient size.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Epidemiology
- 2.1 Disease Background
- 2.2 Risk Factors and Comorbidities
- 2.3 Global Trends
- 2.4 Forecast Methodology
- 2.4.1 Sources Used
- 2.4.2 Forecast Assumptions and Methods
- 2.4.3 Sources Not Used
- 2.5 Epidemiological Forecast for PsA (2015-2025)
- 2.5.1 Diagnosed Prevalent Cases of PsA
- 2.5.2 Age-Specific Diagnosed Prevalent Cases of PsA
- 2.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA
- 2.5.4 Age-Standardized Diagnosed Prevalence of PsA
- 2.5.5 Diagnosed Prevalent Cases by Type
- 2.5.6 Diagnosed Prevalent Cases by Joint Involvement
- 2.6 Alternative Forecast of Diagnosed Prevalent Cases of PsA
- 2.7 Discussion
- 2.7.1 Epidemiological Forecast Insight
- 2.7.2 Limitations of the Analysis
- 2.7.3 Strengths of the Analysis
- 3 Appendix
- 3.1 Physicians and Specialists Included in This Report
- 3.2 About the Authors
- 3.2.1 Epidemiologists
- 3.2.2 Reviewers
- 3.2.3 Global Director of Therapy Analysis and Epidemiology
- 3.3 About GlobalData
- 3.4 About EpiCast
- 3.5 Disclaimer List of Tables
- 1.2 List of Figures
- Figure 1: 7MM, Diagnosed Prevalent Cases of PsA, Ages ≥18 Years, Both Sexes, N, 2015-2025
- Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of PsA, Both Sexes, N, 2015
- Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of PsA, Ages ≥18, 2015
- Figure 4: 7MM, Age-Standardized Diagnosed Prevalence Rate of PsA, Ages ≥18, N, 2015
- Figure 5: 7MM, Diagnosed Prevalent Cases of PsA by Type, Both Sexes, Ages ≥18, 2015
- Figure 6: 7MM, Diagnosed Prevalent Cases of PsA by Joint Involvement, Both Sexes, Ages ≥18, 2015
- Figure 7: 7MM, Alternative Diagnosed Prevalent Cases of PsA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025